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In a previous issue of Critical Care, Schilder and
colleagues report the results of their multicenter trial
(Citrate Anticoagulation Versus Systemic Heparinization;
CASH) comparing regional anticoagulation with citrate
to heparin anticoagulation. They found that citrate was
safer, more efficacious and cheaper than heparin. In
contrast to the largest previous trial, however, a survival
benefit was not found, which was the primary endpoint
of the CASH trial. Different explanations are possible,
including selection bias and a lower severity of disease.
Selection bias was high: only 6% of the renal
replacement therapy patients were included (versus
56% in the previous trial) and exclusion was 56% for
increased risk of bleeding, 2.5 times as frequent as in
the previous trial. Thus, the trial with survival benefit
apparently included more patients with risk of bleeding
and also more severely ill patients and these are the
groups that potentially benefit the most from citrate.
Nevertheless, the CASH trial is the third large
randomized trial showing superiority of citrate over
heparin, supporting the recommendation of citrate as
first choice anticoagulant.need for therapeutic anticoagulation and risk of bleedingContinuous renal replacement therapy (CRRT) is used
for critically ill patients with acute kidney injury in the
setting of multiple organ failure. To prevent clotting in
the extracorporeal circuit, anticoagulation is required.
The commonly used strategies are heparin, causing sys-
temic anticoagulation, and citrate, providing regional
anticoagulation of the circuit. As a result, citrate does
not increase the patient’s risk of bleeding. On account of
this, citrate should be the first choice in critically ill pa-
tients. However, many doctors doubt its safety. The timeCorrespondence: hmoudemans@gmail.com
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unless otherwise stated.has come to drop this delusion. The recently published
multicenter CASH trial (Citrate Anticoagulation versus
Systemic Heparinisation) is the third large randomized
controlled trial in a row showing superiority of citrate
over heparin [1-3]. Citrate was safer, more efficacious
and cheaper. In contrast to the OLVG (Onze Lieve
Vrouwe Gasthuis) trial [2], however, a survival benefit,
which was the primary endpoint of the CASH trial, was
not found.
Differences between the studies
Differences between the trials involve design, selection
bias, patient characteristics, type of heparin, modality of
CRRT and effect on mortality (Table 1). Remarkably, en-
rollment in the CASH trial was extremely slow and the
study was prematurely discontinued. Despite its multi-
center design, it took 6 years to include 139 patients.
Only 139 of 2,300 patients with indication for CRRT
were included. This 6% enrollment rate profoundly con-
trasts with the 56% enrollment rate in the OLVG trial.
Thus, the selection of patients in the CASH trial was ex-
treme, downgrading its generalizability. The authors sug-
gest that the ‘availability of citrate with its longer filter
survival’ raised the threshold for enrollment. However,
were the main reasons for exclusion mentioned in the
CONSORT diagram. Exclusion rates for need for thera-
peutic anticoagulation were 19% (432/1,297) in the CASH
trial and 7% (26/385) in the OLVG trial (P <0.0001). This
difference can partially be explained by a different anticoa-
gulation policy. At the time of the OLVG study, atrial fib-
rillation was not a strict indication for anticoagulation.
Exclusion rates for risk of bleeding were 1,297/2,300
(56%) in the CASH trial and 85/385 (22%) in the OLVG
trial (P <0.0001). Altogether, the CASH trial population
differed from the OLVG population, likely including pa-
tients with a higher bleeding risk.
In addition, patients in the OLVG trial were older and
more severely ill than in both other trials, explaining theed Central Ltd. The licensee has exclusive rights to distribute this article, in any
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Table 1 Comparison between three large randomized controlled trials comparing citrate to heparin anticoagulation for
continuous venovenous hemofiltration
CASH trial 2014 [1]
(multicenter)
OLVG trial 2009 [2]
(single center)
Hetzel trial 2011 [3]
(multicenter)
Excluded
(percentage of patients needing CRRT)
1,297/2,300 (94%) 170/385 (44%) Not reported
Modality Predilution CVVH Postdilution CVVH Predilution CVVH
Groups Citrate Heparin P value Citrate LMWH P value Citrate Heparin P value
Number of included patients 66 73 97 103 87 83
Patient characteristics
Age 67 (36–87) 67 (23–85) 73 (64–79) 73 (67–79) 62 (SD 15) 65 (SD 12)
APACHE II 23 (11–53) 25 (6–43) 28 (27–30) 28 (27–29) 22 (SD 5.1) 22 (SD 5.5)
SOFA 10 (2–19) 11 (3–18) 11 (10–13) 11 (10–14) 10 (SD 3.0) 10 (SD 2.6)
Cause of acute kidney injurya
Septic 41% 37% 43% 49% 77% 75%
Ischemic (cardiogenic + hypovolemic) 50% 51% 80% 61% Not reported
Safety
Adverse events needing discontinuation 5 (8%) 24 (33%) <0.001 2 (2%) 19 (19%) <0.001
Bleeding percentageb 3 (5%) 10 (14%) 0.09 0 (0%) 16 (16%) <0.001 5 (5.7%) 12 (14.7%) 0.09
Citrate accumulation 4 (6%) 1 (1%) 1 (1%)
Efficacy
Circuit survival (hours)c 46 (2–138) 32 (1–72) 0.02 27 (13–47) 26 (15–43) 0.68 38 (SD 23) 26 (SD 19) <0.001
Mortality
90-day 42% 42% 1.00 48% 63% 0.03
28-day 33% 35% 1.00 47% 41%
Values are median (25th to 75th percentile), means (standard deviation (SD)), number (%). aMore causes possible. bCriteria for bleeding differed between studies.
cCalculated for the first filter in the CASH trial, and for all filters in the other two. APACHE, Acute Physiology and Chronic Health Evaluation; CASH, Citrate
Anticoagulation Versus Systemic Heparinization; CRRT, continuous renal replacement therapy; CVVH, continuous venovenous hemofiltration; LMWH, low molecular
weight heparin; OVLG, Onze Lieve Vrouwe Gasthuis; SOFA, Sequential Organ Failure Assessment.
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account of the heparin group), because age and Acute
Physiology and Chronic Health Evaluation (APACHE)
score were independent predictors of mortality in both
studies. Some patients with very low APACHE scores
were included in the CASH trial (Table 1). Finally, the
CASH protocol used predilution CRRT and supple-
mented less magnesium.
Interpretation
We can only speculate whether these differences can ex-
plain why citrate did not confer a survival benefit in the
CASH trial [1] and Hetzel trial [3] but did in the OLVG
trial [2]. In the latter, citrate was especially beneficial in
younger patients and those with more severe organ fail-
ure, in surgical patients and those with sepsis. Subgroup
analysis in the CASH trial did not show significant dif-
ferences, but some trends were similar: the survival
benefit for citrate tended to be higher in younger pa-
tients (odds ratio (OR) 0.61, 95% confidence interval
(CI) 0.31 to 1.83) and those with higher APACHE score
(OR 0.53, 95% CI 0.19 to 1.48). If more patients hadbeen included and the effects were similar, the width of
the CI would have been smaller. No survival benefit was
seen for citrate in the septic population in the CASH
trial, possibly because the more severely ill septic pa-
tients were not included in the CASH trial due to
thrombocytopenia. These patients likely benefit most
from citrate.
Conclusion
The CASH trial confirms the superiority of citrate in pa-
tients without an increased risk of bleeding in terms of
safety and efficacy, while the intervention is less costly.
Citrate confers an even greater benefit when the risk of
bleeding is increased, because CRRT without anticoagu-
lation is really problematic. Randomized studies in this
population will, however, never be available. Thus, stub-
born objectors: surrender! Citrate is the first choice.
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